IM Cannabis Raises US$250K via Convertible Note and 2M+ Warrants — Deeply Dilutive Terms
IMCC sits 25% above its 52-week low of $0.097 on light trading volume (0.1× avg).
Summary
IM Cannabis raised US$250,000 in a convertible note with deeply dilutive terms, including 2.05M warrants, continuing a pattern of high-cost financings amid a going concern warning.
Key Events · Financing and Capital Events · IMCC
-
US$250K Convertible Note Closed
A US$250,000 convertible note was issued to L.I.A. Pure Capital Ltd. at a 10% original issue discount, yielding US$225,000 in net proceeds. The note bears 8% interest (14% upon default) and is not repayable in cash — all obligations are satisfied through share issuance.
-
Highly Dilutive Conversion Terms
The conversion price is the lower of US$0.122 (fixed) or 90% of the lowest VWAP over 20 trading days, with a floor of US$0.02436. At the current stock price of US$0.1211, the variable price could be as low as ~US$0.109, implying significant dilution. The note also includes a 4.99% beneficial ownership cap.
-
2.05M Warrants Issued
Warrants to purchase 2,052,545 common shares at CAD$0.17 per share were issued, exercisable immediately for five years. This represents potential additional dilution of roughly 18% of the current outstanding shares (based on ~11.3M shares outstanding implied by market cap).
-
Registration Obligation
The company must file an F-3 resale registration statement within 30 trading days and use commercially reasonable efforts to have it effective within 60–90 days, enabling the investor to sell the conversion and warrant shares into the market.
Analysis · IMCC · Life Sciences
IM Cannabis closed a US$250,000 convertible note financing with an institutional investor, netting US$225,000 in proceeds. The note converts at the lower of a fixed US$0.122 or 90% of the lowest VWAP over 20 days, with a floor of US$0.02436 — a structure that heavily dilutes existing shareholders if the stock remains depressed. The company also issued 2,052,545 warrants at CAD$0.17, exercisable for five years. This follows two similar US$225,000 financings in June and July, signaling ongoing cash desperation. With a market cap of only ~US$1.1M and a stock price of US$0.1211, the potential dilution from conversion and warrant exercise is enormous relative to the company's size. The going concern warning from May 2026 and the recent director resignation add to the distress picture.
At the time of this filing, IMCC was trading at $0.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.10 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.